Aurobindo receives FDA OK for generic Banzel
Rufinamide tablets are indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older, and in adults.
Aurobindo has received the Food and Drug Administration’s blessing for Rufinamide tablets, 200 mg and 400 mg, which are the generic of Eisai’s Banzel.
Rufinamide tablets are indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older, and in adults.
[Read more: Aurobindo gets FDA nod for 3 generics]
Rufinamide tablets have a market value of roughly $115 million for the 12 months ending April 2023, per IQVIA’s April 2023 data.